Soon-Hyo Kwon, Jae-Woo Choi, Jong-Soo Hong, Sang-Young Byun, Kyoung-Chan Park, Sang-Woong Youn, Chang-Hun Huh, Jung-Im Na
BACKGROUND: Paronychia has been reported in as many as 10% of patients treated with gefitinib. Although conservative management and treatment with topical or systemic antibiotics are beneficial, no effective method exists for intractable cases. Platelet-rich plasma (PRP)consists of a high concentration of platelets that promote wound healing through chemotaxis, cell proliferation,angiogenesis, and tissue remodeling. OBSERVATIONS: We herein report a refractory case of gefitinib-induced paronychia successfully treated with autologous PRP...
December 2012: Archives of Dermatology